Systemic inflammation after drug-eluting stent placement

Journal of Thrombosis and Thrombolysis

Volumn 19, Issue 2, 2005, Pages 87-92

  Gogo Jr , Prospero B ^a   Schneider, David J ^a   Watkins, Matthew W ^a   Terrien, Edward F ^a   Sobel, Burton E ^a   Dauerman, Harold L ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Inflammation; Restenosis; Stent

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTENOSIS; RISK ASSESSMENT; RISK REDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; VEIN DIAMETER; VEIN GRAFT; VENOUS BLOOD;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; SIALOGLYCOPROTEINS; STENTS; TREATMENT OUTCOME;

EID: 23644449359     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-1378-6     Document Type: Article

References (26)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349(14):1315-1323. 10.1056/NEJMoa035071
2. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107(3):381-383. 10.1161/01.CIR.0000051720.59095.6D
3. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109(11):1366-1370. 10.1161/ 01.CIR.0000121358.26097.06
4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350(3):221-231. 10.1056/NEJMoa032441
5. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002;40(11):1935-1942. 10.1016/ S0735-1097(02)02562-7
6. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003;92(8):924-929. 10.1016/S0002-9149(03)00971-8
7. O'Neill WW, Leon MB. Drug-eluting stents: Costs versus clinical benefit. Circulation 2003;107(24):3008-3011. 10.1161/01.CIR.0000079018.84618.0E
8. Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol 2003;10(4):652-657. 10.1128/CDLI.10.4.652-657.2003
9. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 2000;12(11):1712-1716. 10.1006/cyto.2000.0764
10. O'Neill WW, Leon MB. Drug-eluting stents: Costs versus clinical benefit. Circulation 2003;107(24):3008-3011. 10.1161/01.CIR.0000079018.84618.0E
11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349(14):1315-1323. 10.1056/NEJMoa035071
12. O'Neill WW, Leon MB. Drug-eluting stents: Costs versus clinical benefit. Circulation 2003;107(24):3008-3011. 10.1161/01.CIR.0000079018.84618.0E
13. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82(4):515-518. 10.1016/ S0002-9149(98)00370-1
14. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003;92(8):924-929. 10.1016/S0002-9149(03)00971-8
15. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000;21(14):1152-1158. 10.1053/euhj.1999.1987
16. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104(9):992-997. 11524391
17. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: Recommended evaluation from a consensus group. Circulation 2002;106(14):1867-1873. 10.1161/01.CIR.0000033485.20594.6F
18. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350(3):221-231. 10.1056/NEJMoa032441
19. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107(3):381-383. 10.1161/01.CIR.0000051720.59095.6D
20. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting Stent: Should we be cautious? Circulation 2004;109(6):701-705. 10.1161/ 01.CIR.0000116202.41966.D4
21. Lincoff AM, Furst JG, Ellis SG, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997;29(4):808-816. 10.1016/S0735-1097(96)00584-0
22. Aggarwal A, Schneider DJ, Terrien EF, et al. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004;93(1):6-9. 10.1016/j.amjcard.2003.09.003
23. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104(2):163-167. 11447080
24. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104(2):163-167. 11447080
25. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000;21(14):1152-1158. 10.1053/euhj.1999.1987
26. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109(11):1366-1370. 10.1161/ 01.CIR.0000121358.26097.06